Developer docs
API playgroundTry for free, no card

Search company profiles

MVision AI

Full company profile

uuid0000rny

Namestring
MVision AI
Legal namestring
MVision AI
Websiteurl
mvision.ai
Company typeenum
Private
Founded yearint
2017
Descriptiontext

MVision AI is a Helsinki, Finland-based medical software company founded in 2017 that develops AI-powered solutions for radiotherapy treatment planning. The company's product architecture is organized around two commercial offerings: GBS™ (Guideline-Based Segmentation), which bundles the Contour+ auto-segmentation engine with the Guide training and assessment module and the Verify quality-assurance module; and the Workspace+ platform, which integrates Contour+, Dose+ (AI dose prediction for prostate and pelvic radiotherapy), Image+ (synthetic CT for MRI-only workflows), and Adapt+ (contour propagation for adaptive radiotherapy). Underlying technology consists of deep learning models trained on multi-institutional imaging datasets and aligned with international contouring guidelines, achieving a reported median vDSC of 0.88 in clinical evaluations and up to 95% manual-work-time reduction in radiotherapy planning workflows.

The company monetizes through B2B medical-device software licensing on a recurring subscription basis, selling directly to enterprise radiotherapy departments and cancer centers and indirectly via a distributor network (including Synektik in Poland and Meditest in France) and TPS integration partners (Varian, Elekta). Pricing is not publicly disclosed and is typically negotiated per institution. As of the latest data, the platform has been used to treat over 100,000 patients across 14 countries and 40+ clinics. The company maintains a wholly-owned US subsidiary (MVision AI Inc., headquartered in Delray Beach with a San Antonio office) for HIPAA-compliant US market operations. Regulatory footprint is broad, with FDA 510(k) clearances for both Contour+ and Dose+ (Dose+ in September 2025), CE marking, and market approvals in Australia (TGA), Singapore (HSA), UAE, and Morocco. The IAEA/Aarhus University Hospital ELAISA research partnership extends reach into 22 low- and middle-income countries.

Short descriptiontext

MVision AI is a Helsinki-based medical software company that builds AI-powered radiotherapy planning tools. Its Workspace+ platform and GBS™ suite deliver automated organ contouring, dose prediction, and synthetic imaging for cancer centers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHelsinki, Finland
HQ citystring
Helsinki
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiotherapy AI software, cancer treatment planning, medical imaging automation, radiation oncology software, clinical decision support
Industry4 codes
PRIMARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Radiotherapy Treatment Planning Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Software Licensing
TypeSubscription Recurring
Description

MVision AI develops and commercializes AI-powered medical device software solutions (Contour+, Dose+, Image+, Adapt+) for radiotherapy planning. The company operates as a medical software company with products requiring regulatory approvals (FDA 510(k), CE, TGA) for clinical use in various markets.

mvision.ai
2Post Seed Financing
TypeSubscription Recurring
Description

The company raised 5.4 million euros in Post Seed financing to accelerate its AI-powered radiotherapy planning solution development and commercialization.

mvision.ai
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 8 records shown
1GBS™
Description

Guideline-Based Segmentation solution combining Contour+, Guide, and Verify for standardized radiotherapy contouring.

mvision.ai
+7 more records
Core offering1 text field

MVision AI develops and sells a SaaS-based, AI-powered medical device software platform for radiotherapy treatment planning. The offering centers on two integrated solutions—GBS™ (Guideline-Based Segmentation combining Contour+, Guide, and Verify) and Workspace+ (unified platform integrating Contour+, Dose+, Image+, and Adapt+)—that automate organ contouring, dose prediction, synthetic imaging, and adaptive planning to accelerate cancer treatment workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • Platform used to treat over 100,000 patients across 14 countries
+8 more records
Product overview1 text field

MVision AI offers a platform-plus-modules architecture centered on two main solutions: GBS™ (Guideline-Based Segmentation) and Workspace+. GBS™ is a comprehensive solution combining three modules—Contour+ (AI auto-contouring), Guide (contouring training and assessment), and Verify (contour validation)—designed to standardize segmentation and reduce variability. Workspace+ is the unified AI platform that integrates multiple independent modules: Contour+ for auto-segmentation, Dose+ for AI dose prediction, Image+ for synthetic CT imaging, and Adapt+ for contour propagation and adaptation. Both solutions are designed for radiotherapy workflows and support flexible adoption, with modules operating independently or together. The company has received FDA 510(k) clearance, CE certification, and market approvals across multiple countries including Australia, Singapore, UAE, Morocco, and the USA.

Product and service8 records
1GBS™ (Guideline-Based Segmentation)
CategoryRadiotherapy AI software suite
Description

Comprehensive guideline-based segmentation solution for radiotherapy departments that combines AI auto-contouring (Contour+), contouring skills training (Guide), and contour quality assurance (Verify) to standardize planning and reduce inter-clinician variability.

2Workspace+
CategoryRadiotherapy AI platform
Description

Unified AI platform for radiotherapy workflows that brings together contouring, synthetic CT imaging, AI dose prediction, and adaptive contour propagation in one secure environment with flexible modular adoption.

3Contour+
CategoryRadiotherapy AI module — auto-segmentation
Description

AI-powered auto-contouring module that automatically delineates organs at risk and anatomical structures on CT and MRI images for radiotherapy planning across multiple body sites.

4Dose+
CategoryRadiotherapy AI module — dose prediction
Description

AI-powered dose prediction module within Workspace+ that delivers rapid estimation of dose distribution maps to accelerate radiotherapy treatment planning, clinically validated for prostate and pelvic lymph node cases.

5Image+
CategoryRadiotherapy AI module — synthetic imaging
Description

Synthetic CT imaging module within Workspace+ that generates synthetic CT images from MRI to support MRI-only radiotherapy treatment planning workflows.

6Adapt+
CategoryRadiotherapy AI module — adaptive planning
Description

Contour adaptation module within Workspace+ that rapidly propagates and adapts contours to anatomical changes during radiotherapy, supporting adaptive radiotherapy workflows.

7Guide
CategoryRadiotherapy training software
Description

Training and competency assessment module within GBS that benchmarks clinicians against international contouring guidelines and provides feedback to build contouring expertise.

8Verify
CategoryRadiotherapy quality assurance software
Description

Quality assurance module within GBS that validates AI-generated contours against manual contours and monitors inter- and intra-observer variation across the radiotherapy team.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Synektik is a distributor of MVision AI products in Poland, listed on the company's distributor page. They handle local sales, implementation support, and customer relationships for MVision AI solutions in the Polish market.

2Meditest
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Meditest is a partner of MVision AI mentioned in the context of SFPM Scientific Days 2026 event, where they will be present together at the conference in Lyon, France.

mvision.ai
Strategic tierCoreTypeTechnology or Integration
Description

MVision AI solutions are designed for seamless integration with Varian treatment planning systems including TrueBeam, TrueBeam STx, Clinac, and Halcyon. Multiple customer sites use MVision AI alongside Varian equipment.

Strategic tierCoreTypeTechnology or Integration
Description

MVision AI solutions integrate with Elekta treatment planning systems. Clinical sites including Vivantes Berlin-Spandau and Royal Marsden use Elekta equipment alongside MVision AI.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

IAEA partnered with MVision AI for the ELAISA project (Potential of E-Learning interventions for AI-assisted contouring Skills in Radiotherapy), a joint initiative with Aarhus University Hospital evaluating AI-assisted contouring in 22 low- and middle-income countries with 97 radiation oncologists participating.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Joint research partner with IAEA on the ELAISA project, evaluating the impact of e-learning interventions combined with AI-assisted contouring on head and neck cancer OAR delineation skills in radiation oncologists from low- and middle-income countries.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MVision AI collaborates with ESTRO through research presentations at ESTRO conferences, participation in educational workshops, and integration of ESTRO contouring guidelines in product development. The ELAISA project used ESTRO School contouring specialists for training.

8Turku University Hospital
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

First university test hospital for MVision AI products in 2017-2018. Ongoing research collaboration agreement valid until 2027. The site conducts clinical testing of new modules (Image+, Adapt+, Dose+) and provides feedback for product development.

mvision.ai
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Ireland's largest radiotherapy provider treating 5,500+ patients annually. Uses MVision GBS across three sites with active research collaboration including 24 abstracts at ESTRO, including studies on AI auto-contouring workflows, CBCT tracking, and adaptive radiotherapy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Swedish-headquartered incumbent in linear accelerators, brachytherapy, and treatment planning software (Monaco). Like Varian, a broad incumbent in radiation oncology that MVision integrates with but that could also internalize similar AI capabilities.

TypeEmerging player
Description

Paris-based AI company applying deep learning to radiation oncology treatment planning and contouring. An emerging AI-native peer in the same radiotherapy auto-contouring and dose prediction space as MVision, with narrower commercial footprint.

TypeBroad incumbent
Description

Global leader in radiation oncology hardware, treatment planning (Eclipse), and oncology information systems, now part of Siemens Healthineers. The TPS incumbent that MVision integrates with and a potential long-term competitor if it bundles native auto-contouring AI into Eclipse.

TypeDirect peer
Description

US-based vendor of AI-driven workflow automation tools for radiation oncology (AutoContour, ClearCalc, EZFluence, ClearCheck). Directly competes with MVision's Contour+ and Dose+ on AI contouring and treatment planning efficiency in radiotherapy clinics.

TypeDirect peer
Description

Canadian AI company offering auto-contouring (Contour ProtégéAI) and other radiotherapy planning software. Directly competes with MVision on AI auto-segmentation for radiation therapy planning, particularly in clinic-by-clinic sales motions.

TypeBroad incumbent
Description

Large incumbent with imaging and oncology IT offerings that overlap with the radiotherapy planning ecosystem MVision serves. A broad ecosystem player whose strategy around AI auto-contouring could shape the competitive landscape.

TypeDirect peer
Description

Swedish-headquartered vendor of RayStation treatment planning software and the RayCare oncology information system. Directly competes with MVision in radiation oncology planning workflows, including developing its own machine learning auto-contouring capabilities within RayStation.

TypeBroad incumbent
Description

Philips' radiation oncology portfolio includes Pinnacle treatment planning and broader oncology informatics. A broad incumbent offering overlapping capabilities in the radiotherapy workflow where MVision competes and partners.

TypeDirect peer
Description

Oxford-based medical imaging AI company specializing in auto-contouring and image registration for radiation oncology and diagnostic imaging. Overlaps directly with MVision's Contour+ on AI auto-segmentation and serves the same radiotherapy department buyer.

10MIM Software
TypeDirect peer
Description

US-based medical imaging AI vendor with products for radiation oncology contouring, deformable registration, and theranostics. Overlaps with MVision on AI-driven radiotherapy workflow tools and serves similar hospital radiology and radiation oncology customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MVision AI

Radiotherapy Treatment Planning Softwaremvision.ai

MVision AI is a Helsinki-based medical software company that builds AI-powered radiotherapy planning tools. Its Workspace+ platform and GBS™ suite deliver automated organ contouring, dose prediction, and synthetic imaging for cancer centers globally.

What MVision AI does

MVision AI is a Helsinki, Finland-based medical software company founded in 2017 that develops AI-powered solutions for radiotherapy treatment planning. The company's product architecture is organized around two commercial offerings: GBS™ (Guideline-Based Segmentation), which bundles the Contour+ auto-segmentation engine with the Guide training and assessment module and the Verify quality-assurance module; and the Workspace+ platform, which integrates Contour+, Dose+ (AI dose prediction for prostate and pelvic radiotherapy), Image+ (synthetic CT for MRI-only workflows), and Adapt+ (contour propagation for adaptive radiotherapy). Underlying technology consists of deep learning models trained on multi-institutional imaging datasets and aligned with international contouring guidelines, achieving a reported median vDSC of 0.88 in clinical evaluations and up to 95% manual-work-time reduction in radiotherapy planning workflows.

The company monetizes through B2B medical-device software licensing on a recurring subscription basis, selling directly to enterprise radiotherapy departments and cancer centers and indirectly via a distributor network (including Synektik in Poland and Meditest in France) and TPS integration partners (Varian, Elekta). Pricing is not publicly disclosed and is typically negotiated per institution. As of the latest data, the platform has been used to treat over 100,000 patients across 14 countries and 40+ clinics. The company maintains a wholly-owned US subsidiary (MVision AI Inc., headquartered in Delray Beach with a San Antonio office) for HIPAA-compliant US market operations. Regulatory footprint is broad, with FDA 510(k) clearances for both Contour+ and Dose+ (Dose+ in September 2025), CE marking, and market approvals in Australia (TGA), Singapore (HSA), UAE, and Morocco. The IAEA/Aarhus University Hospital ELAISA research partnership extends reach into 22 low- and middle-income countries.

MVision AI firmographics

Firmographics
Name
MVision AI
Legal name
MVision AI
Website
https://mvision.ai
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
MVision AI is a Helsinki-based medical software company that builds AI-powered radiotherapy planning tools. Its Workspace+ platform and GBS™ suite deliver automated organ contouring, dose prediction, and synthetic imaging for cancer centers globally.
Ownership category
akta.pro rank

MVision AI industry classification

Industry
Product category
Radiotherapy Treatment Planning Software
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAHABAH
Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Radiotherapy AI software
  • Cancer treatment planning
  • Medical imaging automation
  • Radiation oncology software
  • Clinical decision support

Where MVision AI is headquartered

Location

Headquarters

HQ city
Helsinki
HQ country
Finland
HQ region
Europe

Offices3 records

Markets served

MVision AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Medical Device Software Licensing: MVision AI develops and commercializes AI-powered medical device software solutions (Contour+, Dose+, Image+, Adapt+) for radiotherapy planning. The company operates as a medical software company with products requiring regulatory approvals (FDA 510(k), CE, TGA) for clinical use in various markets.
  2. Post Seed Financing: The company raised 5.4 million euros in Post Seed financing to accelerate its AI-powered radiotherapy planning solution development and commercialization.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

MVision AI product offering

Product offering

Core offering

MVision AI develops and sells a SaaS-based, AI-powered medical device software platform for radiotherapy treatment planning. The offering centers on two integrated solutions—GBS™ (Guideline-Based Segmentation combining Contour+, Guide, and Verify) and Workspace+ (unified platform integrating Contour+, Dose+, Image+, and Adapt+)—that automate organ contouring, dose prediction, synthetic imaging, and adaptive planning to accelerate cancer treatment workflows.

Product overview

MVision AI offers a platform-plus-modules architecture centered on two main solutions: GBS™ (Guideline-Based Segmentation) and Workspace+. GBS™ is a comprehensive solution combining three modules—Contour+ (AI auto-contouring), Guide (contouring training and assessment), and Verify (contour validation)—designed to standardize segmentation and reduce variability. Workspace+ is the unified AI platform that integrates multiple independent modules: Contour+ for auto-segmentation, Dose+ for AI dose prediction, Image+ for synthetic CT imaging, and Adapt+ for contour propagation and adaptation. Both solutions are designed for radiotherapy workflows and support flexible adoption, with modules operating independently or together. The company has received FDA 510(k) clearance, CE certification, and market approvals across multiple countries including Australia, Singapore, UAE, Morocco, and the USA.

Differentiator

Problem solved

Functional benefit

Brands

  • GBS™: Guideline-Based Segmentation solution combining Contour+, Guide, and Verify for standardized radiotherapy contouring.
  • Workspace+™
  • Contour+
  • Dose+
  • Image+
  • Adapt+
  • Guide
  • Verify

Products and services

  • GBS™ (Guideline-Based Segmentation) Comprehensive guideline-based segmentation solution for radiotherapy departments that combines AI auto-contouring (Contour+), contouring skills training (Guide), and contour quality assurance (Verify) to standardize planning and reduce inter-clinician variability.
  • Workspace+ Unified AI platform for radiotherapy workflows that brings together contouring, synthetic CT imaging, AI dose prediction, and adaptive contour propagation in one secure environment with flexible modular adoption.
  • Contour+ AI-powered auto-contouring module that automatically delineates organs at risk and anatomical structures on CT and MRI images for radiotherapy planning across multiple body sites.
  • Dose+ AI-powered dose prediction module within Workspace+ that delivers rapid estimation of dose distribution maps to accelerate radiotherapy treatment planning, clinically validated for prostate and pelvic lymph node cases.
  • Image+ Synthetic CT imaging module within Workspace+ that generates synthetic CT images from MRI to support MRI-only radiotherapy treatment planning workflows.
  • Adapt+ Contour adaptation module within Workspace+ that rapidly propagates and adapts contours to anatomical changes during radiotherapy, supporting adaptive radiotherapy workflows.
  • Guide Training and competency assessment module within GBS that benchmarks clinicians against international contouring guidelines and provides feedback to build contouring expertise.
  • Verify Quality assurance module within GBS that validates AI-generated contours against manual contours and monitors inter- and intra-observer variation across the radiotherapy team.

Quantifiable outcome

  • Platform used to treat over 100,000 patients across 14 countries
  • +8 more outcomes

Companies that use MVision AI

Customer profile

Named customers14 records

Segments4 records

Ideal customer profiles2 records

MVision AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

MVision AI partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and flagship.

  • SynektikcoreChannel Partner/ Reseller/ DistributorSynektik is a distributor of MVision AI products in Poland, listed on the company's distributor page. They handle local sales, implementation support, and customer relationships for MVision AI solutions in the Polish market.
  • MeditestcoreChannel Partner/ Reseller/ DistributorMeditest is a partner of MVision AI mentioned in the context of SFPM Scientific Days 2026 event, where they will be present together at the conference in Lyon, France.
  • Varian (Siemens Healthineers)coreTechnology or IntegrationMVision AI solutions are designed for seamless integration with Varian treatment planning systems including TrueBeam, TrueBeam STx, Clinac, and Halcyon. Multiple customer sites use MVision AI alongside Varian equipment.
  • ElektacoreTechnology or IntegrationMVision AI solutions integrate with Elekta treatment planning systems. Clinical sites including Vivantes Berlin-Spandau and Royal Marsden use Elekta equipment alongside MVision AI.
  • International Atomic Energy Agency (IAEA)flagshipStrategic or Co-development PartnerIAEA partnered with MVision AI for the ELAISA project (Potential of E-Learning interventions for AI-assisted contouring Skills in Radiotherapy), a joint initiative with Aarhus University Hospital evaluating AI-assisted contouring in 22 low- and middle-income countries with 97 radiation oncologists participating.
  • Aarhus University HospitalflagshipStrategic or Co-development PartnerJoint research partner with IAEA on the ELAISA project, evaluating the impact of e-learning interventions combined with AI-assisted contouring on head and neck cancer OAR delineation skills in radiation oncologists from low- and middle-income countries.
  • ESTRO (European Society for Therapeutic Radiology and Oncology)coreStrategic or Co-development PartnerMVision AI collaborates with ESTRO through research presentations at ESTRO conferences, participation in educational workshops, and integration of ESTRO contouring guidelines in product development. The ELAISA project used ESTRO School contouring specialists for training.
  • Turku University HospitalflagshipStrategic or Co-development PartnerFirst university test hospital for MVision AI products in 2017-2018. Ongoing research collaboration agreement valid until 2027. The site conducts clinical testing of new modules (Image+, Adapt+, Dose+) and provides feedback for product development.
  • St. Luke's Radiation Oncology Network (SLRON)flagshipStrategic or Co-development PartnerIreland's largest radiotherapy provider treating 5,500+ patients annually. Uses MVision GBS across three sites with active research collaboration including 24 abstracts at ESTRO, including studies on AI auto-contouring workflows, CBCT tracking, and adaptive radiotherapy.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

MVision AI competitors and assessment

Company assessment

Broad incumbents

  • Elekta: Swedish-headquartered incumbent in linear accelerators, brachytherapy, and treatment planning software (Monaco). Like Varian, a broad incumbent in radiation oncology that MVision integrates with but that could also internalize similar AI capabilities.
  • Varian (Siemens Healthineers): Global leader in radiation oncology hardware, treatment planning (Eclipse), and oncology information systems, now part of Siemens Healthineers. The TPS incumbent that MVision integrates with and a potential long-term competitor if it bundles native auto-contouring AI into Eclipse.
  • GE Healthcare (Radiation Oncology): Large incumbent with imaging and oncology IT offerings that overlap with the radiotherapy planning ecosystem MVision serves. A broad ecosystem player whose strategy around AI auto-contouring could shape the competitive landscape.
  • Philips (Radiation Oncology): Philips' radiation oncology portfolio includes Pinnacle treatment planning and broader oncology informatics. A broad incumbent offering overlapping capabilities in the radiotherapy workflow where MVision competes and partners.

Emerging players

  • Therapanacea: Paris-based AI company applying deep learning to radiation oncology treatment planning and contouring. An emerging AI-native peer in the same radiotherapy auto-contouring and dose prediction space as MVision, with narrower commercial footprint.

Direct peers

  • Radformation: US-based vendor of AI-driven workflow automation tools for radiation oncology (AutoContour, ClearCalc, EZFluence, ClearCheck). Directly competes with MVision's Contour+ and Dose+ on AI contouring and treatment planning efficiency in radiotherapy clinics.
  • Limbus AI: Canadian AI company offering auto-contouring (Contour ProtégéAI) and other radiotherapy planning software. Directly competes with MVision on AI auto-segmentation for radiation therapy planning, particularly in clinic-by-clinic sales motions.
  • RaySearch Laboratories: Swedish-headquartered vendor of RayStation treatment planning software and the RayCare oncology information system. Directly competes with MVision in radiation oncology planning workflows, including developing its own machine learning auto-contouring capabilities within RayStation.
  • Mirada Medical: Oxford-based medical imaging AI company specializing in auto-contouring and image registration for radiation oncology and diagnostic imaging. Overlaps directly with MVision's Contour+ on AI auto-segmentation and serves the same radiotherapy department buyer.
  • MIM Software: US-based medical imaging AI vendor with products for radiation oncology contouring, deformable registration, and theranostics. Overlaps with MVision on AI-driven radiotherapy workflow tools and serves similar hospital radiology and radiation oncology customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

MVision AI social profiles

Digital presence

MVision AI compliance and trust

Trust signal

Compliance4 records

MVision AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MVision AI leadership team

Management profile

Number of profiles

Profiles4 records

MVision AI subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MVision AI funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MVision AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MVision AI

What does MVision AI do?

MVision AI develops and sells a SaaS-based, AI-powered medical device software platform for radiotherapy treatment planning. The offering centers on two integrated solutions—GBS™ (Guideline-Based Segmentation combining Contour+, Guide, and Verify) and Workspace+ (unified platform integrating Contour+, Dose+, Image+, and Adapt+)—that automate organ contouring, dose prediction, synthetic imaging, and adaptive planning to accelerate cancer treatment workflows.

Is MVision AI a public or private company?

MVision AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was MVision AI founded?

MVision AI was founded in 2017. It employs 51 to 100 people.

Where is MVision AI based?

MVision AI is headquartered in Helsinki, Finland, in the Europe region.

How does MVision AI make money?

Two revenue lines are on record. Medical Device Software Licensing is the primary driver. The others are post Seed Financing.

Who are MVision AI's main competitors?

Broad incumbents on record are Elekta, Varian (Siemens Healthineers), GE Healthcare (Radiation Oncology) and Philips (Radiation Oncology). Therapanacea is listed as an emerging player. Direct peers are Radformation, Limbus AI, RaySearch Laboratories, Mirada Medical and MIM Software.

Does MVision AI have an API?

No public API is recorded for MVision AI.

What industry is MVision AI in?

MVision AI's product category is Radiotherapy Treatment Planning Software. Its primary akta.pro industry code is HLAHABAH, Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 3391 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireAI Tele-Oncology Radiation Dose Scheduler Market Set to More Than Double During 2026-2030, Reaching USD 2.28 BillionThe AI tele-oncology radiation dose scheduler market is projected to grow from $0.81 billion in 2025 to $2.28 billion by 2030, at a CAGR of 23.3%, driven by increasing cancer incidence, adoption of tele-oncology platforms, and demand for precise radiation dose calculations. In March 2025, Finland-based MVision AI launched Dose+, an AI tool for personalized radiation dose distribution, while Baylor College of Medicine partnered with mVIZION.ai to advance AI innovations in radiation therapy planning. North America leads the market in 2025, with Asia-Pacific expected to be the fastest-growing region during the forecast period.GlobeNewswirePhilips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025Philips unveiled Rembra RT and Areta RT CT platforms and a helium-free BlueSeal RT 1.5T MR system at ASTRO 2025. The CT systems offer ultra-fast reconstruction up to 106 images per second and a 20-year service guarantee, while BlueSeal RT uses AI-based SmartSpeed Precise and is helium-free. Philips is also exploring integration of MVision AI's Contour+ auto-segmentation software.Stock TitanPhilips Launches New CT, MR Systems for Radiation Therapy PlanningPhilips unveiled new CT and MR systems for radiation therapy planning at ASTRO 2025, including Rembra RT, Areta RT, and BlueSeal RT. The CT platforms offer ultra-fast reconstruction up to 106 images per second and a 20-year service guarantee, while BlueSeal RT is a helium-free 1.5T MR system. Philips is also exploring integration with MVision AI's Contour+ software.GlobeNewswirePhilips unveils latest CT and MR innovations in radiation therapy, advancing precision cancer care at ASTRO 2025Philips unveiled Rembra RT and Areta RT CT platforms and a helium-free BlueSeal RT 1.5T MR system at ASTRO 2025. The CT systems offer ultra-fast reconstruction up to 106 images per second and a 20-year service guarantee, while BlueSeal RT uses AI-based SmartSpeed Precise and is helium-free. Philips is also exploring integration with MVision AI's Contour+ auto-segmentation.openPR.comUnited States AI in Oncology Market Growth Powered by Precision Medicine & Clinical AI Adoption | Major Players: Azra Al, CureMetrix, Inc., ConcertAI, Immunai, MVision AI Inc., Paige AI, Inc.The global AI in oncology market reached US$2.43 billion in 2024 and is projected to reach US$22.85 billion by 2033, a CAGR of 25.3%. North America leads, with U.S. developments including expanded regulatory clearances and partnerships in 2025.MvisionSafe and Ethical AI in Radiation Oncology: Regulations and MVision’s ComplianceThe article reviews global regulatory frameworks for AI in healthcare, noting that most are soft law, and details the EU AI Act's risk-based requirements for high-risk systems, including data governance, documentation, transparency, human oversight, and security. It cites implementation deadlines of August 2024, August 2025 and August 2026, and fines up to 7% of global turnover. It then outlines how MVision's AI Contour+ complies with these standards.IrishtechnewsMVision raise 5.4 million euros to treat cancer with AIMVision AI has raised 5.4 million euros in Post Seed financing to enhance its AI-powered cancer treatment planning solution. The funding will accelerate the automation of cancer treatment processes, thereby reducing patient waiting times significantly from weeks to days. MVision's technology has already been used to treat over 100,000 cancer patients across 14 countries.EgirisimYapay zeka desteğiyle kanser tedavisini hızlandırmak isteyen MVision AI, 5.4 milyon euro yatırım aldıMVision AI, radyoterapi planlaması için yapay zeka tabanlı bir bulut yazılımı geliştiren şirket, J12 Ventures ve Voima Ventures'tan 5.4 milyon euro yatırım aldı. Şirket, teknolojisinin 14 ülkede 100.000'den fazla hastanın tedavisini hızlandırdığını belirtirken, fonları tedavi sürecini iyileştirmek ve küresel platformunu genişletmek amacıyla kullanacak.MvisionPress Release: MVision AI raises 5.4M€ to make same-day cancer treatment the new standardMVision AI has secured 5.4 million euros in Post Seed financing led by J12 Ventures and Voima Ventures to accelerate the development of its cloud-based AI radiotherapy planning solution. The technology automates cancer treatment segmentation, significantly reducing waiting times from weeks to days for patients undergoing radiotherapy. This funding will support the expansion of their platform, which has already treated over 100,000 patients across 14 countries.